SONoALS

Transforming ALS Diagnosis and Drug Discovery

Breakthrough diagnosis and treatments
—reimagining ALS care with cutting-edge technology.

Scroll

About SONoALS

Mission-Driven Science

SONoALS, Inc. is a pioneering startup to redefine how ALS is diagnosed and treated. Our mission is to bring non-invasive, data-rich monitoring to the frontlines of neurodegenerative disease research. The team unites clinical neuroscience and biomedical engineering to make that mission a reality.

Breakthrough Technology

Wearable Ultrasound × AI-Powered Analysis

Revolutionary ultrasound technology combined with AI-powered analysis for Amyotrophic Lateral Sclerosis (ALS) monitoring and diagnosis.

SONoALS Ultrasound Technology

Wearable Ultrasound Device Prototype

  • Minimized ultrasound probe via a hub, allowing direct attachment to the skin
  • Connectable to a laptop for simultaneous 4-muscle measurement & recording for 20 minutes in a resting state
  • Acquired data is sent to the AI analysis server to display results
Overall View

Overall View

詳細を見る
Probe & Hub Close-up

Probe & Hub Close-up

詳細を見る
Probe Close-up 1

Probe Close-up 1

詳細を見る
Probe Close-up 2

Probe Close-up 2

詳細を見る

Application & Measurement Images

Attachment State 1

Attachment State 1

詳細を見る
Attachment State 2

Attachment State 2

詳細を見る
Attachment State 3

Attachment State 3

詳細を見る

Precision Tools for ALS Research and Beyond

Transforming healthcare through innovative applications in early diagnosis and drug discovery.

Healthcare Applications - Remote Monitoring and Telemedicine

Applications

Early and Non-invasive Diagnosis of ALS

  • Fasciculations are one of the biomarkers that appear earlier than needle EMG abnormalities.

Drug Discovery Support

Fasciculation biomarkers responding in days

  • Pre-clinical drug screening in humans
  • Selection of responder groups
  • Significant reduction in clinical trial duration
  • Personalized medicine

We aim to realize these goals.

News & Press

Latest updates and achievements from SONoALS

Jun 2, 2026

Interview article published in Kei-Do

An interview with CEO Saeki has been published in Kei-Do, a media platform for business leaders, covering the origins and future vision of SONoALS' ALS early diagnosis and clinical trial support

Read more
May 21, 2026

Spoke at MedTech Angels Season 5 Demo Day

CEO Saeki joined the "Season 4 Alumni's One Year" panel as the Season 4 Grand Prize Winner at the Demo Day, held at Nihonbashi Life Science Hub (hybrid event)

Read more
May 12, 2026

Pitched at NQ Health Accelerator Demo Day

Pitched as one of the 16 selected startups at the Demo Day held at Nakanoshima Qross Qrossover Lounge "Yume"

Read more

Get in Touch

Ready to learn more about our revolutionary ALS technology? Let's connect.

Company Information

Address

WALLSQUARE Kitanozaka
2-13-15 Yamamoto Ave., Chuo Ward
Kobe City, Hyogo 650-0003, Japan

Established

May 2025

CEO, SONoALS

Chizu Saeki, MD, Ph.D.

Founder & CEO, SONoALS

LinkedIn Profile
CTO/COO, SONoALS

Tadashi Kojima

CTO/COO, SONoALS